Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the Netherlands

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults2025 · 38 citations
2. 2Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18–49 years at increased risk for severe RSV disease2026
3. 3Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults2025 · 27 citations
4. 4Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States: Clinical and Economic Value2025 · 3 citations
5. 5Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50–59 Years at Increased Risk of Severe RSV Disease2025